Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and. | April 17, 2023
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentations.
Full abstracts of the following presentations are available online at www.aacr.org:
Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia